Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — Biotech Showcase 2019
26 slides from Kazia Therapeutics's conference presentation, Jan 8, 2019
Slide 1: Kazia Presentation to Biotech Showcase (ASX Release)
ASX RELEASE 7 January 2019 KAZIA PRESENTATION TO BIOTECH SHOWCASE Sydney, 7 January 2019 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide a copy of the presentation which is to be presented by Dr James Garner at Biotec
Slide 2: A clinical-stage oncology company with two novel agents in development
A clinical-stage oncology company with two novel agents in development Presentation to Biotech Showcase #BTS19 San Francisco, CA 8 January 2019 ASX: KZA | NASDAQ : KZIA | Twitter: @KaziaTx
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the “safe- harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual
Slide 4: Kazia has four ongoing clinical trials across two novel programs
Kazia has four ongoing clinical trials across two novel programs Preclinical Phase I Phase II Phase III Glioblastoma Multiforme (GBM) (Kazia-sponsored) GDC-0084 Breast Cancer Brain Metastases (BCBM) PI3K / mTOR (collaboration with Dana- Inhibitor Farber Cancer Institute) Diffuse Intrinsic Licensed f
Slide 5: Kazia has delivered all milestones for 2018, with high-value data read-outs expected in 2019
Kazia has delivered all milestones for 2018, with high-value data read-outs expected in 2019 ✓ ✓ ✓ GDC-0084 Commence Commence Data read-out Data read-out Receipt of Start of phase potential other from phase 2a from phase 2a Orphan Drug 2a study in collaborations potential study (safety study Designa
Slide 6: GDC-0084 Phase II Glioblastoma Multiforme
GDC-0084 Phase II Glioblastoma Multiforme 4
Slide 7: Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer
Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer Lung No clear 3-4 months 12-15 cause untreated months Breast or strong risk survival average 14 million factors survival with cancer cases treatment per annum Colon Any age, Five-year Prostate but most survival co
Slide 8: Current standard of care is essentially ineffective in approximately 65% of GBM cases
Current standard of care is essentially ineffective in approximately 65% of GBM cases Standard of Care Debulking surgery Radiotherapy + Temozolomide (‘Stupp where possible temozolomide maintenance therapy Regimen’) 6 weeks 4w 6 x 28-day cycles ~35% of patients respond GDC-0084 is being developed for
Slide 9: In GDC-0084 phase 1, 7/27 patients showed a metabolic partial response
In GDC-0084 phase 1, 7 / 27 patients (26%) showed a ‘metabolic partial response’ on FDG-PET Pre-Dosing On GDC-0084 Pre-Dosing On GDC-0084 Analysis courtesy of Professor Ben Ellingson, UCLA Brain Tumor Imaging Laboratory 7
Slide 10: The PI3K class has been further validated with a third approved therapy, but GDC-0084 is unique
The PI3K class has been further validated with a third approved therapy, but GDC-0084 is unique Zydelig (idelalisib) Aliqopa (copanlisib) Copiktra (duvelisib) GDC-0084 FDA Approved FDA Approved FDA Approved In phase II human trials July 2014 ✓ September 2017 ✓ October 2018 ✓ under US FDA oversight (
Slide 11: GDC-0084 is currently in a phase 2a study in GBM, with multiple data-readouts during 2019
GDC-0084 is currently in a phase 2a study in GBM, with multiple data-readouts during 2019 ‘Phase 2a’ Component Step 1 Step 2 Step 3 Dose Optimisation Expansion Cohort Planned Registration Trial 6 – 24 patients 20 patients 12 months 6 months March 1H 2H (potentially) 2018 2019 2019 2023 Dosing Dosing
Slide 12: Brain metastases represent a significant expansion to the commercial opportunity for GDC-0084
INDICATIVE Brain metastases represent a significant expansion to the commercial opportunity for GDC-0084 Glioblastoma HER2+ Breast Cancer Other potential future indications Approximately 130,000 patients Approximately 340,000 patients per annum worldwide per annum worldwide $2.3 billion $12.7 billio
Slide 13: GDC-0084 analogue has shown good preclinical evidence of activity in breast cancer brain mets
GDC-0084 analogue has shown good preclinical evidence of activity in breast cancer brain mets Source: Breast Cancer Res Treat. (2017):164(3):581-591 11
Slide 14: Recent data from Novartis at ESMO showed impressive results for PI3K inhibitor in breast cancer
Recent data from Novartis at ESMO showed impressive results for PI3K inhibitor in breast cancer • Alpelisib (BYL719) is a PI3K inhibitor being developed for breast cancer • Alpelisib only inhibits the alpha form of PI3K, and was not developed to cross the blood-brain barrier; GDC-0084 inhibits all f
Slide 15: GDC-0084 value proposition is considerable
GDC-0084 value proposition is considerable • Currently in Phase II clinical trials, under IND with US FDA, at leading US centers for brain cancer • Clear Phase I data, with favourable safety profile and indications of efficacy in late-stage GBM patients • Clear unmet medial need, with only existing
Slide 16: Cantrixil Phase I Ovarian Cancer
Cantrixil Phase I Ovarian Cancer 14
Slide 17: Cantrixil phase 1 study has now progressed into Part B, and data is expected in calendar 2019
Cantrixil phase 1 study has now progressed into Part B, and data is expected in calendar 2019 Part A: Dose Escalation ✓ Part B: Dose Expansion • 3 to 42 patients in up to 8 • 12 patients, all at 5 mg/kg cohorts • Seeks to provide potential • Seeks to establish maximum efficacy signals tolerated dose
Slide 18: Part A has already shown evidence of activity with one partial responder to date
Part A has already shown evidence of activity with one partial responder to date October 2017 (baseline) January 2018 Source: images courtesy of Professor Jim Coward, Icon Cancer Centre 16
Slide 19: Corporate Summary
Corporate Summary 17
Slide 20: Kazia is NASDAQ & ASX listed
Kazia is NASDAQ & ASX listed Share Price (US$) KZIA 7.00 Current Assets (Jun 18) Debt US$ 6.9 million Nil 6.00 Market Capitalisation US$ 17 million 5.00 NASDAQ: KZIA (1:10 ratio) Listing 4.00 ASX: KZA NASDAQ: 0.4% /day Average Daily Volume 3.00 ASX: 0.1% /day NASDAQ: US$ 100K /day 2.00 Average Daily
Slide 21: Other companies have built successful businesses around in-licensed products
Other companies have built successful businesses around in-licensed products (NASDAQ: TSRO) (NASDAQ: PBYI) (NASDAQ: CLVS) US$ billion US$ billion US$ billion 3 $2.4 3 3 $2.5 $2.2 billion billion billion 2 2 2 $360 $440 $291 1 1 1 million million million 0 0 0 IPO (2012) Current IPO (2012) Current IP
Slide 22: Other companies focused on the PI3K pathway have been highly-valued in the market
Other companies focused on the PI3K pathway have been highly-valued in the market Single asset company with one PI3K US$ 140 million inhibitor in phase I human trials Market Cap One PI3K inhibitor in phase II human US$ 430 million trials, one other drug in phase III, and two in animal testing Market
Slide 23: Kazia is now well-funded to see both programs through key data read-outs in calendar 2019
Kazia is now well-funded to see both programs through key data read-outs in calendar 2019 Current funding allows:- $9.3M ~$3.5M* $3.4M • Completion of phase IIa Current assets as at Shares in Noxopharm Proceeds (pre-costs) GDC-0084 trial 30 June 2018 (ASX:NOX) from institutional placement in Oct 18
Slide 24: A strong team brings international experience in big pharma and early-stage biotech
A strong team brings international experience in big pharma and early-stage biotech Board Scientific Advisory Board Iain Ross Professor Sir Murray Brennan Chairman Emeritus Chairman of Cancer Surgery at Memorial Sloan Kettering Executive and Board roles in pharma Hospital, New York and small biotech
Slide 25: Kazia has become a compelling investment proposition
Kazia has become a compelling investment proposition 1• Lead program, GDC-0084, sourced from Genentech, the world’s most successful cancer drug developer 2• Class of drugs, PI3K inhibitors, is well-validated and resurgent, but GDC-0084 is uniquely differentiated by ability to cross the blood-brain b
Slide 26: www.kaziatherapeutics.com
www.kaziatherapeutics.com